Efficacy and safety of novel carbapenem-β-lactamase inhibitor combinations: Results from phase II and III trials.

ABSTRACT:

Objectives

The addition of novel β-lactamase inhibitors to carbapenems restores the activity against multidrug-resistant Gram-negative bacteria. The aim of this study was to summarize the evidence on the efficacy and safety of novel carbapenem-β-lactamase inhibitor combinations.

Methods

We conducted a meta-analysis of clinical trials comparing novel carbapenem-β-lactamase inhibitor combinations with comparators to assess the clinical and microbiological responses, mortality, and adverse events (AEs).

Results

A total of 1,984 patients were included. The pooled risk ratios (RRs) of clinical cure, microbiological eradication, all-cause mortality, and 28-day mortality were 1.11 (95% CI: 0.98-1.26), 0.98 (95% CI: 0.82-1.16), 0.90 (95% CI: 0.49-0.94), and 0.68 (95% CI: 0.49

SUBMITTER: Yu W 

PROVIDER: S-EPMC9538188 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature